Glenmede Trust’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.1M | Buy |
1,517,586
+220,403
| +17% | +$2.13M | 0.1% | 172 |
|
|
2026
Q1 | $9.63M | Sell |
1,297,183
-113,652
| -8% | -$1.2M | 0.05% | 341 |
|
|
2025
Q4 | $16.6M | Buy |
+1,410,835
| New | +$15.2M | 0.08% | 216 |
|
|
2025
Q1 | $10.5M | Sell |
1,109,577
-37,143
| -3% | -$464K | 0.06% | 345 |
|
|
2024
Q4 | $18.9M | Sell |
1,146,720
-8,719
| -0.8% | -$135K | 0.1% | 213 |
|
|
2024
Q3 | $17M | Sell |
1,155,439
-16,295
| -1% | -$255K | 0.08% | 256 |
|
|
2024
Q2 | $16.3M | Buy |
1,171,734
+6,742
| +0.6% | +$95.6K | 0.08% | 250 |
|
|
2024
Q1 | $18.3M | Buy |
1,164,992
+78,469
| +7% | +$1.21M | 0.09% | 231 |
|
|
2023
Q4 | $17.6M | Sell |
1,086,523
-27,868
| -3% | -$456K | 0.09% | 220 |
|
|
2023
Q3 | $13.7M | Sell |
1,114,391
-12,490
| -1% | -$186K | 0.08% | 260 |
|
|
2023
Q2 | $19.5M | Buy |
1,126,881
+2,270
| +0.2% | +$37.4K | 0.11% | 196 |
|
|
2023
Q1 | $19.6M | Buy |
1,124,611
+15,265
| +1% | +$217K | 0.11% | 196 |
|
|
2022
Q4 | $10.3M | Sell |
1,109,346
-147,940
| -12% | -$1.38M | 0.06% | 325 |
|
|
2022
Q3 | $10.8M | Buy |
1,257,286
+72,615
| +6% | +$721K | 0.07% | 300 |
|
|
2022
Q2 | $9.65M | Buy |
1,184,671
+499,788
| +73% | +$4.77M | 0.06% | 353 |
|
|
2022
Q1 | $8.32M | Buy |
684,883
+207,370
| +43% | +$4.36M | 0.04% | 388 |
|
|
2021
Q4 | $16.3M | Buy |
477,513
+140,124
| +42% | +$5.49M | 0.08% | 294 |
|
|
2021
Q3 | $16.3M | Sell |
337,389
-7,635
| -2% | -$353K | 0.08% | 268 |
|
|
2021
Q2 | $15.6M | Sell |
345,024
-1,617
| -0.5% | -$71.6K | 0.08% | 273 |
|
|
2021
Q1 | $16.7M | Sell |
346,641
-86,077
| -20% | -$4.48M | 0.09% | 252 |
|
|
2020
Q4 | $23.3M | Sell |
432,718
-208,868
| -33% | -$9.44M | 0.13% | 191 |
|
|
2020
Q3 | $23.7M | Sell |
641,586
-87,710
| -12% | -$3.26M | 0.14% | 169 |
|
|
2020
Q2 | $22.6M | Sell |
729,296
-332,970
| -31% | -$9.23M | 0.14% | 180 |
|
|
2020
Q1 | $31.1M | Hold |
1,062,266
| – | – | 0.14% | 198 |
|
|
2019
Q4 | $31.1M | Sell |
1,062,266
-141,881
| -12% | -$3.38M | 0.14% | 198 |
|
|
2019
Q3 | $23M | Sell |
1,204,147
-97,869
| -8% | -$2.3M | 0.11% | 256 |
|
|
2019
Q2 | $28.6M | Buy |
1,302,016
+1,105,970
| +564% | +$24.3M | 0.13% | 235 |
|
|
2019
Q1 | $4.01M | Buy |
196,046
+195,161
| +22,052% | +$3.39M | 0.02% | 511 |
|
|
2018
Q4 | $11K | Sell |
885
-6,640
| -88% | -$99K | ﹤0.01% | 2233 |
|
|
2018
Q3 | $114K | Buy |
+7,525
| New | +$104K | ﹤0.01% | 1280 |
|
Other funds holding NEO
FLAM
GF
NAMI
B
Glenmede Trust's NEO Position: Q2 2026 in Review
Glenmede Trust increased its NeoGenomics (NEO) stake by 17% in Q2 2026, buying an estimated $2.13M and bringing the position to 1,517,586 shares worth $22.1M. The position accounts for 0.1% of the portfolio, ranked #172.
Glenmede Trust first reported a position in NEO in Q3 2018 and has held it in 30 quarters since. The position peaked at $31.1M in Q1 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.
- Glenmede Trust held 1,517,586 shares of NeoGenomics worth $22.1M as of Q2 2026.
- Glenmede Trust bought 220,403 NeoGenomics shares in Q2 2026, an estimated $2.13M.
- NeoGenomics made up 0.1% of Glenmede Trust's portfolio in Q2 2026, its #172 holding.
- Glenmede Trust first reported a position in NeoGenomics in Q3 2018 and has held it in 30 quarters since.
- Glenmede Trust's NeoGenomics position peaked at $31.1M in Q1 2020.
- 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.